Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Weakness Disorders
- The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.
- Treatments for progressive weakness syndromes should total nearly $14.6 billion in 2012 and $22.8 billion in 2017, a CAGR of 9.4%.
- Treatments for multiple sclerosis should total nearly $12.6 billion in 2012 and $19.5 billion in 2017, a CAGR of 9.2%.
BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for treatments of neurodegenerative (i.e., progressive ataxia and weakness) disorders. The key objective is to present a comprehensive analysis and the future direction of treatments for these disorders as the market efforts toward drug and therapy development evolve.
This report explores present and future strategies within the progressive ataxia and weakness disorders market, which includes treatments and therapies for dysfunctions, including progressive ataxia and progressive weakness disorder syndromes. The market’s improvisation, setbacks and needs are also discussed. The comparisons, usage, advantages and disadvantages of different types of technologies, including small-molecule and monoclonal antibodies, are also presented.
A detailed analysis of the industry structure has been conducted. Revenues are broken down by the neurodegenerative dysfunction. Sales figures are estimated for the five-year period from 2012 through 2017.
The report discusses applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology. The report also covers significant patents and their allotments in each category.
REASONS FOR DOING THIS STUDY
Extensive research in the field of progressive ataxia and weakness disorders as well as collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technology development is providing modifying therapies for the late stages of these disorders. Collaborations among research institutes and pharmaceutical companies are becoming more common, as state-of-the-art technology is being explored to develop more-efficient products and therapies.
R&D spending, increasing competition, patent expiries and new technologies are shifting the market in a new direction. The market’s overall revenue has increased from 2009 to 2011, and it continues to show growth, as new advancements, product launches and collaborations will have positive influences for the foreseeable future. This study looks at most of the systems affected by these factors.
Acquisition strategies and company collaborations are also covered in this report. This study discusses the strength and weaknesses of each technology in light of the new developments, growing competition and changing customer needs.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This study contributes to the areas of market growth in Friedreich’s ataxia, Gerstmann-Straussler-Scheinker disease, Machado-Joseph disease, amyotrophic lateral sclerosis, progressive bulbar palsy, hereditary spastic paraplegia, hereditary neuropathies and multiple sclerosis. Pharmaceutical biotechnical companies, research institutes and physicians will find this study of interest.
SCOPE OF THE STUDY
The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the regulatory environments, and the technologies involved, as well as market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes such countries as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand.
Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals, among other sources. Data were collected through interviews and correspondence with technical experts at companies that manufacture enzyme inhibitors. Projections were based on estimates that were calculated such using information as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Many companies within the industry were surveyed to obtain data for this study. These included manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease-sector industries. Data were gathered from various industry sources. BCC spoke with officials within the industry and also reviewed newsletters, company literature and product literature, as well as a host of technical articles, journals, indices and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
BCC ON-LINE SERVICES
BCC Research offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:
- Examine the complete BCC Research catalog of market research reports and place direct orders.
- Subscribe to any of BCC Research’s many industry newsletters.
- Read announcements of recently published reports and newly launched newsletters.
- Register for its well-known conferences.
- Request additional information on any BCC research product.
- Take advantage of special offers.
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.